Rituximab had a consistent safety profile through multiple courses used in treating (RA) during 11 years of observation and was not associated with excess infection rates, cardiac events, or malignancies. Medscape, 09/01/2015. (Also see Treatments for Rheumatoid Arthritis and Biologic Agents)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.